Your browser doesn't support javascript.
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage.
Chemaitelly, Hiam; Ayoub, Houssein H; Coyle, Peter; Tang, Patrick; Yassine, Hadi M; Al-Khatib, Hebah A; Smatti, Maria K; Hasan, Mohammad R; Al-Kanaani, Zaina; Al-Kuwari, Einas; Jeremijenko, Andrew; Kaleeckal, Anvar Hassan; Latif, Ali Nizar; Shaik, Riyazuddin Mohammad; Abdul-Rahim, Hanan F; Nasrallah, Gheyath K; Al-Kuwari, Mohamed Ghaith; Butt, Adeel A; Al-Romaihi, Hamad Eid; Al-Thani, Mohamed H; Al-Khal, Abdullatif; Bertollini, Roberto; Abu-Raddad, Laith J.
  • Chemaitelly H; Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar. hsc2001@qatar-med.cornell.edu.
  • Ayoub HH; World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar. hsc2001@qatar-med.cornell.edu.
  • Coyle P; Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA. hsc2001@qatar-med.cornell.edu.
  • Tang P; Mathematics Program, Department of Mathematics, Statistics, and Physics, College of Arts and Sciences, Qatar University, Doha, Qatar.
  • Yassine HM; Hamad Medical Corporation, Doha, Qatar.
  • Al-Khatib HA; Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar.
  • Smatti MK; Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, United Kingdom.
  • Hasan MR; Department of Pathology, Sidra Medicine, Doha, Qatar.
  • Al-Kanaani Z; Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar.
  • Al-Kuwari E; Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar.
  • Jeremijenko A; Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar.
  • Kaleeckal AH; Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar.
  • Latif AN; Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar.
  • Shaik RM; Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar.
  • Abdul-Rahim HF; Department of Pathology, Sidra Medicine, Doha, Qatar.
  • Nasrallah GK; Hamad Medical Corporation, Doha, Qatar.
  • Al-Kuwari MG; Hamad Medical Corporation, Doha, Qatar.
  • Butt AA; Hamad Medical Corporation, Doha, Qatar.
  • Al-Romaihi HE; Hamad Medical Corporation, Doha, Qatar.
  • Al-Thani MH; Hamad Medical Corporation, Doha, Qatar.
  • Al-Khal A; Hamad Medical Corporation, Doha, Qatar.
  • Bertollini R; Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
  • Abu-Raddad LJ; Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar.
Nat Commun ; 13(1): 4675, 2022 08 09.
Article in English | MEDLINE | ID: covidwho-1984386
ABSTRACT
There is significant genetic distance between SARS-CoV-2 Omicron (B.1.1.529) variant BA.1 and BA.2 sub-lineages. This study investigates immune protection of infection with one sub-lineage against reinfection with the other sub-lineage in Qatar during a large BA.1 and BA.2 Omicron wave, from December 19, 2021 to March 21, 2022. Two national matched, retrospective cohort studies are conducted to estimate effectiveness of BA.1 infection against reinfection with BA.2 (N = 20,994; BA.1-against-BA.2 study), and effectiveness of BA.2 infection against reinfection with BA.1 (N = 110,315; BA.2-against-BA.1 study). Associations are estimated using Cox proportional-hazards regression models after multiple imputation to assign a sub-lineage status for cases with no sub-lineage status (using probabilities based on the test date). Effectiveness of BA.1 infection against reinfection with BA.2 is estimated at 94.2% (95% CI 89.2-96.9%). Effectiveness of BA.2 infection against reinfection with BA.1 is estimated at 80.9% (95% CI 73.1-86.4%). Infection with the BA.1 sub-lineage appears to induce strong, but not full immune protection against reinfection with the BA.2 sub-lineage, and vice versa, for at least several weeks after the initial infection.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Reinfection / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Variants Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-32363-4

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Reinfection / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Variants Limits: Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-32363-4